红日药业(300026) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥1,588,644,754.71, representing a decrease of 20.58% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥118,289,981.94, down 40.63% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,572,170.92, a decrease of 50.00% compared to the previous year[7] - Total operating revenue for the third quarter was CNY 4,900,224,293.30, a decrease of 10.67% compared to CNY 5,486,439,217.46 in the same period last year[30] - The net profit for the current period is 469,484,920.92, a decrease of 25.2% compared to 627,306,052.40 in the previous period[32] - The total profit for the current period is 571,274,481.71, down from 766,195,077.14, reflecting a decline of 25.5%[32] - The operating profit for the current period is 542,007,469.41, compared to 754,222,342.94 in the previous period, indicating a decrease of 28.1%[32] - The total comprehensive income for the current period is 489,833,240.84, compared to 629,052,999.17 in the previous period, a decrease of 22.2%[35] - Basic earnings per share for the current period is 0.16, down from 0.21, reflecting a decline of 23.8%[35] Research and Development - R&D expenses for the period amounted to ¥176,091,200, an increase of 52.06% year-on-year, indicating increased investment in research and development[14] - Research and development expenses increased to CNY 176,091,216.83, up from CNY 115,803,855.49, indicating a focus on innovation and new product development[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,995,272,284.07, reflecting a growth of 3.34% from the end of the previous year[7] - The total assets reached CNY 11,995,272,284.07, compared to CNY 11,607,300,738.29 in the previous year, showing growth in asset base[29] - Non-current assets totaled CNY 5,111,440,203.53, an increase from CNY 4,801,037,420.21, highlighting investment in long-term assets[29] - The company's total liabilities were CNY 3,676,580,575.85, slightly up from CNY 3,654,921,077.43, indicating stable financial leverage[29] - The equity attributable to shareholders increased to CNY 8,143,563,383.56 from CNY 7,772,888,664.89, reflecting improved profitability and retained earnings[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥252,779,423.82, down 33.83% compared to the same period last year[7] - The cash flow from operating activities for the current period is 252,779,423.82, down from 382,031,160.81, a decline of 33.9%[36] - The cash flow from investing activities shows a net outflow of -508,830,755.94, compared to -397,030,866.12 in the previous period, indicating an increase in outflow[38] - The cash flow from financing activities has a net outflow of -104,473,550.90, contrasting with a net inflow of 566,554,801.03 in the previous period[38] - The total cash and cash equivalents at the end of the period is 956,712,079.30, down from 1,635,365,692.54, a decrease of 41.5%[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 138,546, with a total shareholding of 243,820,162 shares pledged[16] - The company reported a total of 305,408,770 restricted shares, with 873,750 shares released during the period[22] - The top shareholder, Chengdu Xingcheng Investment Group Co., Ltd., holds 667,997,417 shares, representing a significant portion of the company's equity[22] - The total number of restricted shares held by the top 10 shareholders remains unchanged at 294,196,979 shares for Yao Xiaoqing[19] Strategic Developments - The company has no new strategies or significant events reported in the third quarter[25] - The company has not reported any new product developments or technological advancements in the latest quarter[25] - There are no mergers or acquisitions mentioned in the third quarter report[25] - The company is exploring market expansion opportunities, although specific strategies were not disclosed in the report[30] - The company maintained a strong cash position, with cash flow metrics to be elaborated in subsequent disclosures, ensuring liquidity for future investments[30] Other Financial Metrics - The weighted average return on equity was 1.46%, down 1.16% from the previous year[7] - The company reported a significant increase in prepayments, which rose by 54.92% year-on-year, indicating higher procurement payments[12] - As of September 30, 2022, the total current assets amounted to CNY 6,883,832,080.54, an increase from CNY 6,806,263,318.08 at the beginning of the year[23] - The cash and cash equivalents decreased to CNY 976,261,663.49 from CNY 1,315,964,613.66 at the beginning of the year[23] - Accounts receivable stood at CNY 3,292,614,423.39, down from CNY 3,506,551,341.00 at the start of the year[23] - Inventory increased to CNY 1,849,163,017.45 from CNY 1,304,511,820.13 at the beginning of the year[23] - The company reported a foreign currency translation difference of 16,990,172.50, compared to -2,510,018.74 in the previous period, indicating a positive change[35]